Signati Medical wins FDA IDE approval for Separo vasectomy device trial
Signati Medical has received US Food and Drug Administration approval of its Investigational Device Exemption application for a pivotal clinical study of the Separo Vessel Sealing System, an energy-based platform designed specifically for vasectomy procedures. The clearance marks a significant regulatory step for the Providence, Rhode Island company, moving it from preclinical development into a formal randomised controlled trial.
The Separo system is an energy-based vessel-sealing device intended to reduce the technical variability associated with conventional vasectomy techniques. Signati's proposition is that purpose-built instrumentation — rather than general-purpose electrosurgical tools adapted for the procedure — can standardise outcomes and improve the overall patient experience for men seeking permanent contraception.
The pivotal study
The approved study is a randomised, controlled, open-label, multi-centre, non-inferiority investigation enrolling up to 120 adult male subjects across as many as five US institutions. Participants will be randomised to the Separo system or to mucosal cautery vasectomy, which is the prevailing standard of care. The primary effectiveness endpoint is azoospermia or rare non-motile sperm — defined as no more than 100,000 non-motile sperm per millilitre — confirmed by post-vasectomy semen analysis within six months of the procedure. This criterion aligns with widely accepted clinical thresholds for confirming sterility.
William Prentice, president and chief executive of Signati Medical, is named in contact materials but did not issue a substantive quote in the release. The company was founded on the premise, as it describes it, that men deserve purpose-built options for participating in shared family planning decisions.
Signati has been transparent that regulatory clearance alone is not the finish line. The pivotal RCT has been structured with guideline incorporation and payer coverage as explicit downstream objectives. The non-inferiority design, multi-centre enrolment, and objective semen analysis endpoint are calibrated to meet the evidentiary standards that professional urology societies and both public and commercial insurers typically require before updating clinical guidelines or extending reimbursement to new devices.
Market and competitive context
Vasectomy is well established as one of the more cost-efficient and clinically effective forms of long-term contraception, but uptake among men in the United States has historically lagged behind female sterilisation. Research cited in the release, including a 2023 commentary in Perspectives on Sexual and Reproductive Health, estimates that female sterilisation rates run approximately three times higher than male sterilisation nationally — a gap attributed to awareness deficits, provider variation and the absence of standardised tooling.
The medical device market for male reproductive health has historically attracted limited dedicated investment compared with analogous female reproductive technology segments, which has meant that vasectomy has been performed largely with general electrosurgical equipment. Signati's positioning is that a segment-specific device can drive procedural consistency and, by extension, accelerate adoption among both urologists and the patients they counsel.
The device is not currently approved or marketed in any country, and the company has included the standard FDA disclaimer that the Separo system is not intended to diagnose, treat, cure or prevent any disease. The pivotal study design nonetheless reflects a mature regulatory strategy: a head-to-head comparison against the established standard of care is the class of evidence that typically underpins a de novo or 510(k) premarket submission, depending on the FDA's final classification determination. Investors and clinicians will be watching for enrolment timelines and, eventually, the primary endpoint readout as the key near-term milestones in Signati's path to commercialisation.